Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
320 participants
INTERVENTIONAL
2011-09-30
2015-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
160 patients (age \< 38 yr) with AN and 160 age-matched controls (CON) will be enrolled in this study. The areal bone mineral density (aBMD) will be determined using dual-X-ray absorptiometry. Calciotropic hormones, bone turnover markers will be concomitantly evaluated.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with anorexia nervosa
This arm is the experimental arm composed of patients
clinical parameters description
description of weight, height, Bone Mass Index, dietary questionnary, amenorrhea time, pathology time for the two arms
para clinical parameters description
description of DMO, mass, basal metabolism, IGF-1/IGFBP-3 for the two arms
hormonal parameters dosing
dosing of leptine, leptine receptor, adiponectine, ghreline for the two arms
bone modeling markers dosing
dosing of osteocalcine, bone alkalin phosphatase, C-telopeptide of type-I collagene, osteoprotegerine/ RANKL for the two arms
controls subjects
This arm is composed of healthy volunteers
clinical parameters description
description of weight, height, Bone Mass Index, dietary questionnary, amenorrhea time, pathology time for the two arms
para clinical parameters description
description of DMO, mass, basal metabolism, IGF-1/IGFBP-3 for the two arms
hormonal parameters dosing
dosing of leptine, leptine receptor, adiponectine, ghreline for the two arms
bone modeling markers dosing
dosing of osteocalcine, bone alkalin phosphatase, C-telopeptide of type-I collagene, osteoprotegerine/ RANKL for the two arms
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
clinical parameters description
description of weight, height, Bone Mass Index, dietary questionnary, amenorrhea time, pathology time for the two arms
para clinical parameters description
description of DMO, mass, basal metabolism, IGF-1/IGFBP-3 for the two arms
hormonal parameters dosing
dosing of leptine, leptine receptor, adiponectine, ghreline for the two arms
bone modeling markers dosing
dosing of osteocalcine, bone alkalin phosphatase, C-telopeptide of type-I collagene, osteoprotegerine/ RANKL for the two arms
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Health Insurance regimen or benefit from an health insurance regimen
* Aged from 14 to 38 years old
* Women
* No pregnant
Patient suffering from anorexia nervosa defined by criteria of Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)
* Normal menstrual cycles,
* No lifetime history of eating disorders,
* BMI between 18 and 25 kg/m²
Exclusion Criteria
* Disease or treatment may be induce osteoporosis
* In exclusion period in relation with another study
* Law protected subject
14 Years
38 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Montpellier
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Patrick PL LEFEBVRE, MD
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Montpellier
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU de Montpellier - Département d'Endocrinologie Diabète
Montpellier, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UF 8751
Identifier Type: -
Identifier Source: org_study_id